The upgrade in the price target by a reputable analyst like Daniel Grosslight from Citigroup is a strong positive signal for Hims & Hers Health. It suggests confidence in the company's future performance and growth prospects, likely leading to increased investor interest and potentially a rise in the stock price in the short term.